Back to News index

CMA investigation into lithium based medicines

Warwick Smith, Director General of Medicines UK, said: "We note the announcement from the CMA but it would be inappropriate to comment on the specifics of an on-going investigation into lithium based medicines. However, we have consistently stated that we will condemn any action which would artificially manipulate or raise prices where there are no clear patient benefits or supply issues. In our experience, generic firms faced with difficult commercial decisions or where prices become unsustainably low will take into account their own market share and act responsibly so any decisions do not adversely put patient access at risk."